Allena Pharmaceuticals (NASDAQ:ALNA) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Risk and Volatility
Allena Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
This table compares Allena Pharmaceuticals and Outlook Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
84.4% of Allena Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Outlook Therapeutics shares are owned by institutional investors. 36.7% of Allena Pharmaceuticals shares are owned by insiders. Comparatively, 11.5% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Allena Pharmaceuticals and Outlook Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Allena Pharmaceuticals||N/A||N/A||-$21.65 million||($4.80)||-1.66|
|Outlook Therapeutics||$3.09 million||17.90||-$30.09 million||N/A||N/A|
Allena Pharmaceuticals has higher earnings, but lower revenue than Outlook Therapeutics.
This is a summary of current ratings and target prices for Allena Pharmaceuticals and Outlook Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Allena Pharmaceuticals presently has a consensus price target of $31.17, suggesting a potential upside of 292.03%. Given Allena Pharmaceuticals’ higher possible upside, analysts plainly believe Allena Pharmaceuticals is more favorable than Outlook Therapeutics.
Allena Pharmaceuticals beats Outlook Therapeutics on 8 of the 10 factors compared between the two stocks.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company’s lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
About Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for Allena Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allena Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.